Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Cash for cravings: study tests if money motivates weight loss

NCT ID NCT04770909

Disease control Sponsor: University of Wisconsin, Madison Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether giving small weekly cash incentives (up to $300 total) for tracking what you eat and losing weight helps adults with obesity shed pounds. Over 700 participants were followed for 18 months. The goal was to see if these rewards lead to at least 5% weight loss at 26 weeks and beyond.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
cash incentives for dietary self-monitoring and weight loss
What this could lead to
If it works, this could point toward a simple, low-cost way to help people with obesity lose weight and keep it off.
What could go wrong
This is a completed behavioral study, not a drug trial. Results may not apply to everyone, and weight loss may not be sustained long-term.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

706 people

The number who actually took part.

Started

May 2021

Finished

Apr 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * BMI ≥30 kg/m2 * Desire to lose weight * Agrees to attend outcome visits per protocol * Available for class times * Transportation and ability to attend in-person study visits at baseline (screening), 26, 52, and 78 weeks * Able to stand for weight measurements without assistance * Able to speak and read English * Able to download and use the MyFitnessPal and Fitbit apps daily * Possess smart phone with data and texting plan * Have or willing to create a Gmail address * Able to connect to a video conference call using a smartphone, tablet or computer with a webcam and microphone * Score of at least 4 out of 6 on a validated cognitive screener Exclusion Criteria: * Weight \>380 lb * Weight loss of at least 10 lbs in the month prior to screening * Currently enrolled or enrolled in previous month in a clinical, research, or community program focusing on lifestyle change that could affect weight * Current use of weight loss medication * History of bariatric surgery or planning to have bariatric surgery in the study timeframe * Residing in a nursing home or receiving home health care * Impaired hearing * Significant dementia, drug or alcohol misuse, or unstable psychiatric illness (e.g., schizophrenia, psychosis) * Current treatment for cancer or being treated for cancer (besides basal cell carcinoma or squamous cell) in the last 6 months * Use of insulin, sulfonylureas, or meglitinides due to increased risk for hypoglycemia * Pregnant, breastfeeding, or planning to become pregnant within the study timeframe * Diuretic medication doses higher than hydrochlorothiazide 25 mg daily, furosemide 40 mg daily, torsemide 20 mg daily, bumetanide 1 mg daily, or any use of metolazone; use of potassium-sparing diuretics is acceptable * Chronic kidney disease at stage 4 or 5 * Unstable heart disease in the 6 months prior to screening * Exertional chest pain * History of ascites requiring paracentesis * Pain, fainting or other conditions that prohibit mild/moderate exercise

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Obesity are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Obesity obesity disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Obesity

Contacts and locations

Locations

  • Duke University Medical Center

    Durham, North Carolina, 27705, United States

  • University of Wisconsin-Madison

    Madison, Wisconsin, 53705, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.